Vyzulta: how international patients access US-sourced specialty supply

This page is informational, not medical advice. Always work with a licensed treating physician on prescribing decisions. Reserve Meds does not make insurance or pharmacy-assistance-program promises.

Quick orientation

Vyzulta (latanoprostene bunod ophthalmic solution 0.024 percent) is sponsored by Bausch + Lomb and received first US FDA approval in 2017. It is delivered as ophthalmic, one drop in the affected eye(s) once daily in the evening. The US label covers reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Mechanistically, Vyzulta is a nitric-oxide donating prostaglandin F2-alpha analogue.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

US wholesale acquisition cost (WAC) is the published US specialty-distribution list price and is not the same as a single-payer negotiated price. US WAC for Vyzulta commonly runs around USD 300 to USD 400 per 30-day supply. Patient out-of-pocket via cross-border supply is the US WAC plus logistics, IOR / customs, translation, and a Reserve Meds concierge fee; it is not a route to local-formulary pricing.

Mechanism of action

Vyzulta is a nitric-oxide donating prostaglandin F2-alpha analogue. After ocular instillation it splits into latanoprost acid (which lowers intraocular pressure via increased uveoscleral outflow, the standard prostaglandin pathway) and butanediol mononitrate (a nitric-oxide donor that increases trabecular meshwork outflow). The dual mechanism reduces IOP further than latanoprost alone in head-to-head data.

Why Vyzulta routes via cross-border NPP internationally

Vyzulta is a US-led product. Many MENA and South Asian glaucoma protocols stock generic latanoprost or fixed-dose prostaglandin combinations; the nitric-oxide donating presentation specifically is not broadly stocked. Patients stable on Vyzulta or those whose treating ophthalmologist wants the dual-mechanism IOP-lowering profile typically route via named-patient import. Pediatric off-label use varies by region and is physician-directed.

The patterns that produce cross-border demand for Vyzulta are consistent across destination countries: meaningful registration lag relative to the US label, indication-specific dosing complexity that makes substitution clinically risky, payer denial patterns that exclude newer or expanded indications, and the global specialty distribution model in which the originator manufacturer routes specialty supply through a small number of authorized US wholesalers. Reserve Meds sits inside that authorized supply lane, not outside it.

How Reserve Meds coordinates supply

Every Vyzulta case follows the same physician-led, document-first workflow:

1. The treating physician issues a prescription and clinical justification letter.
2. Reserve Meds clinical and regulatory review assesses indication fit and destination-country pathway eligibility.
3. Country-specific named-patient or personal-import documentation is prepared, translated where required, and submitted to the destination-country regulator under the local lawful import framework.
4. Supply is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability (a federal track-and-trace requirement) and unbroken chain of custody from US warehouse forward.
5. Cold-chain handling is validated where applicable; temperature is monitored end-to-end with audit logs.
6. Shipment is coordinated to the patient's treating physician or hospital pharmacy, not directly to consumers.

Reserve Meds does not handle controlled substances. We do not promise pharmacy assistance program enrollment, manufacturer copay support, or insurance reimbursement; those are different commercial frameworks aimed at US-domiciled patients.

Common cross-border destinations

Vyzulta cross-border demand concentrates in markets where US specialty supply is the most reliable path to the labeled indication. We publish destination-country deep-dives where local matrix cells exist; the rest are coordinated case-by-case on the same physician-led workflow.

Across each of these destinations, three structural patterns repeat. First, the local regulator maintains a named-patient or personal-import framework precisely so clinicians can reach a labeled US therapy for individual patients whose case cannot wait for full local registration. Second, that framework is document-driven, which means the work of cross-border access is the work of preparing a defensible clinical and regulatory dossier rather than chasing inventory. Third, the destination-country specialist (the treating physician) signs the case in; Reserve Meds operates on top of that signature, not in place of it.

Real cost picture

Monthly drug-only cost at US WAC commonly runs USD 300 to USD 400. Vyzulta is stored under refrigeration prior to opening and at controlled room temperature once opened; logistics is relatively modest. Reserve Meds quotes firm pricing post-document review.

A formal Reserve Meds quote breaks out: drug cost at US WAC; cold-chain 3PL handling where applicable; IOR, customs, and destination-country regulatory fees; certified translation of physician documentation; and a tiered Reserve Meds concierge fee layered on the drug cost rather than per-dose. The indicative range above is for orientation; a firm quote is issued after physician documentation is reviewed.

Reserve Meds does not charge intake deposits. Patients pay the firm-quoted amount in full only after accepting the quote, with a defined refund posture for procurement failure or gross negligence as set out in the engagement documentation. Delivery or transit-failure outcomes are handled via insurance and replacement coordination rather than refund, because once a US procurement chain is committed, the drug is committed.

Manufacturer context and global distribution

Vyzulta is manufactured by Bausch + Lomb. Like most US specialty therapies, it is routed through a narrow set of authorized specialty wholesalers under DSCSA (Drug Supply Chain Security Act) track-and-trace rules. That is the same supply lane US specialty pharmacies use; cross-border named-patient access works by attaching destination-country regulatory documentation to a shipment that originates inside that authorized lane, not by sourcing outside it. Counterfeit and parallel-trade exposure is concentrated outside that lane, which is precisely why Reserve Meds will not source from secondary or grey-market channels regardless of price.

Serial-number traceability is preserved end-to-end. Every Vyzulta pack or vial carries the US wholesaler's lot and serial-number documentation forward into the destination-country regulatory submission, which is what allows the destination regulator to verify provenance on inspection.

What your physician provides

For Reserve Meds to coordinate Vyzulta, the treating physician provides a treating-ophthalmologist prescription, a clinical justification letter documenting glaucoma type and IOP-control history, baseline IOP and visual field, an iris-pigmentation / periorbital fat / eyelash counseling note (prostaglandin-class effects), and license verification. Reserve Meds does not substitute for treating-physician judgment, does not prescribe, and does not advise on individual patient suitability; that is the treating physician's role.

Common questions

How is Vyzulta different from latanoprost?

Vyzulta releases latanoprost acid plus a nitric-oxide donor, so it works on both uveoscleral and trabecular outflow. Latanoprost alone works mainly on uveoscleral outflow.

Is Vyzulta indicated in pediatrics?

The US label is in adults. Pediatric use varies regionally and is off-label and specialist-directed.

Are the cosmetic side effects the same as latanoprost?

Yes. Iris pigmentation change, periorbital fat changes, and eyelash growth are class effects.

Does it require cold chain?

Refrigerated storage prior to opening; controlled room temperature once opened.

Can it be combined with timolol or alpha-2 agonists?

Yes, fixed-dose pairings are commonly used in glaucoma protocols. Coordination with the treating ophthalmologist is essential.

Indicative timing

Time-to-first-dose for Vyzulta is dominated by destination-country regulatory turnaround on the named-patient or personal-import submission, not by US procurement (which is typically days, not weeks, for an authorized specialty wholesaler with serialized stock). In faster markets (UAE Ministry of Health and Prevention named-patient track, Saudi SFDA named-patient track), the regulatory clock is commonly under 4 weeks when the dossier is complete on first submission. In slower markets or where translations and additional attestations are required, the regulatory clock can extend to 6 to 10 weeks. Reserve Meds frames every Vyzulta timeline as an indicative range with a defined gating event (regulator acknowledgement), not as a guaranteed delivery date.

Subsequent cycles are materially faster than the first cycle because the regulatory file, physician credentials, and import authorization are already on record. For chronic-use therapies like Vyzulta, the first cycle carries the regulatory overhead; the rest is logistics.

Where Reserve Meds fits in

Reserve Meds is the named cross-border coordinator. A dedicated patient coordinator owns the case from intake through delivery, the clinical and regulatory teams handle the document chain, and a DSCSA-compliant specialty wholesaler is the source of every vial or pack. We work in service of the treating-physician relationship, not around it.

Patients deal with one named coordinator from intake through delivery. Physicians deal with a clinical-and-regulatory contact who speaks the language of the destination regulator and of US specialty pharmacy. That single-point-of-contact structure is deliberate: cross-border specialty access fails most often at the seams between parties, not inside any single step, and Reserve Meds is built to own the seams.

Next step

Submit a 60-second intake. Our clinical team will respond as our first cohort opens with case-specific feasibility, a country pathway, an indicative timeline, and a formal quote. Reserved for you.

Start your caseWhatsApp